Yelena Y. Janjigian
0000-0002-5357-5858
Publication & Citation Trends
Publications
715 total
Gastric cancer PDF
Cited by 184
OpenAlex
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial PDF
Cited by 199
OpenAlex
Abstract CT132: A Phase I/IIa clinical trial (TranStar101) to evaluate the safety, tolerability and pharmacokinetics of OSEMITAMAB administered as monotherapy or in combination with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors
Cited by 5
Semantic Scholar
Abstract 3629: Prevalence of claudin18.2 expression in gastric/gastroesophageal junction adenocarcinoma among patients in TranStar101 and TranStar102 clinical trials
Cited by 0
Semantic Scholar
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study
Cited by 310
OpenAlex
Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study PDF
Cited by 213
OpenAlex
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline PDF
Cited by 188
OpenAlex
P-126 TROPION-PanTumor03, a phase 2, multicentre study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients with advanced/metastatic solid tumours: Substudies in gastric and colorectal cancer OA
Cited by 3
Semantic Scholar
Research Topics
Gastric Cancer Management and Outcomes
(468)
Esophageal Cancer Research and Treatment
(348)
Lung Cancer Treatments and Mutations
(213)
Cancer Immunotherapy and Biomarkers
(159)
Cancer Genomics and Diagnostics
(92)
Frequent Co-Authors
Affiliations
U.S. National Science Foundation
Memorial Sloan Kettering Cancer Center
The University of Texas MD Anderson Cancer Center
Bayer (United States)
Merck (Germany)